Literature DB >> 25543122

SATB1 and 2 in colorectal cancer.

Jason Brocato1, Max Costa2.   

Abstract

The special AT-rich sequence-binding proteins 1 and 2 (SATB1/2) are nuclear matrix associated proteins that are transcription factors involved in chromatin remodeling and gene regulation. Expression of the SATB2 gene is tissue-specific, and the only epithelial cells expressing SATB2 are the glandular cells of the lower gastrointestinal tract where its expression is regulated by microRNA-31 (miR-31) and miR-182. SATB2, along with its homolog SATB1, are thought to be involved in various cancers with their roles in this disease being specific to the type of cancer. Colorectal cancer (CRC) provides the largest association of SATB2 with cancer and the roles of SATB2 are better defined and more studied in CRC than in any other cancer type. SATB1 displays a negative association with SATB2 in CRC. The various studies that have investigated the involvement of SATB1 and 2 in CRC have produced consistent findings. Here, we form four major conclusions regarding the role of these proteins in CRC and their potential clinical value: (i) SATB2 is a sensitive marker to distinguish CRC from other cancer types, (ii) Reduced expression of SATB2 in CRC is associated with poor prognosis, (iii) High levels of SATB1 expression facilitate CRC and are associated with poor prognosis and (iv) Overexpression of miR-31 and -182 in CRC leads to more aggressive cancer. This review will describe several of the key investigations that established these conclusions and highlight results that offer opportunities for future research in the treatment and diagnosis of CRC.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25543122      PMCID: PMC4400443          DOI: 10.1093/carcin/bgu322

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  82 in total

Review 1.  Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy.

Authors:  Luca Gattinoni; Yun Ji; Nicholas P Restifo
Journal:  Clin Cancer Res       Date:  2010-08-05       Impact factor: 12.531

2.  [Expression of special AT-rich sequence-binding protein in bladder urothelial carcinoma and its clinical significance].

Authors:  Chun-xiao Liu; Yong Wen; Kai Xu; Shao-bo Zheng; Ya-wen Xu; Bin-shen Chen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2010-06

3.  miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma.

Authors:  Chung-Ji Liu; Meng-Miao Tsai; Pei-Shih Hung; Shou-Yen Kao; Tsung-Yun Liu; Kou-Juey Wu; Shih-Hwa Chiou; Shu-Chun Lin; Kuo-Wei Chang
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

4.  Upregulation of special AT-rich-binding protein 1 by Epstein-Barr virus latent membrane protein 1 in human nasopharyngeal cells and nasopharyngeal cancer.

Authors:  Kazuhira Endo; Julia Shackelford; Mitsuharu Aga; Tomokazu Yoshizaki; Joseph S Pagano
Journal:  J Gen Virol       Date:  2012-12-05       Impact factor: 3.891

5.  MicroRNA-182-5p targets a network of genes involved in DNA repair.

Authors:  Keerthana Krishnan; Anita L Steptoe; Hilary C Martin; Shivangi Wani; Katia Nones; Nic Waddell; Mythily Mariasegaram; Peter T Simpson; Sunil R Lakhani; Brian Gabrielli; Alexander Vlassov; Nicole Cloonan; Sean M Grimmond
Journal:  RNA       Date:  2012-12-18       Impact factor: 4.942

6.  Special AT-rich sequence-binding protein 1 promotes cell growth and metastasis in colorectal cancer.

Authors:  Xue-Feng Fang; Zhi-Bo Hou; Xin-Zheng Dai; Cong Chen; Jing Ge; Hong Shen; Xiao-Feng Li; Li-Ke Yu; Ying Yuan
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

7.  Up-regulation of miR-182 expression in colorectal cancer tissues and its prognostic value.

Authors:  Hui Liu; Lutao Du; Zhihua Wen; Yongmei Yang; Juan Li; Lili Wang; Xin Zhang; Yimin Liu; Zhaogang Dong; Wei Li; Guixi Zheng; Chuanxin Wang
Journal:  Int J Colorectal Dis       Date:  2013-03-10       Impact factor: 2.571

8.  SATB1 overexpression promotes malignant T-cell proliferation in cutaneous CD30+ lymphoproliferative disease by repressing p21.

Authors:  Yang Wang; Xiaoguang Gu; Gaolei Zhang; Lin Wang; Tingting Wang; Yun Zhao; Xiuyan Zhang; Youwen Zhou; Marshall Kadin; Ping Tu
Journal:  Blood       Date:  2014-04-18       Impact factor: 22.113

9.  SATB1 expression is associated with biologic behavior in colorectal carcinoma in vitro and in vivo.

Authors:  Jie Zhang; Baogang Zhang; Xumei Zhang; Yingui Sun; Xiaolong Wei; Michael A McNutt; Shijun Lu; Yuqing Liu; Donghong Zhang; Mingyu Wang; Zhijuan Lin; Na Niu
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

10.  microRNA-182 targets special AT-rich sequence-binding protein 2 to promote colorectal cancer proliferation and metastasis.

Authors:  Min-Hui Yang; Jiang Yu; Dong-Mei Jiang; Wen-Lu Li; Shuang Wang; Yan-Qing Ding
Journal:  J Transl Med       Date:  2014-05-01       Impact factor: 5.531

View more
  18 in total

1.  SATB2 expression increased anchorage-independent growth and cell migration in human bronchial epithelial cells.

Authors:  Feng Wu; Ashley Jordan; Thomas Kluz; Steven Shen; Hong Sun; Laura A Cartularo; Max Costa
Journal:  Toxicol Appl Pharmacol       Date:  2016-01-11       Impact factor: 4.219

2.  SATB2 targeted by methylated miR-34c-5p suppresses proliferation and metastasis attenuating the epithelial-mesenchymal transition in colorectal cancer.

Authors:  Jingfeng Gu; Guiqi Wang; Haixia Liu; Chaohui Xiong
Journal:  Cell Prolif       Date:  2018-04-27       Impact factor: 6.831

3.  Satb1 Regulates Contactin 5 to Pattern Dendrites of a Mammalian Retinal Ganglion Cell.

Authors:  Yi-Rong Peng; Nicholas M Tran; Arjun Krishnaswamy; Dimitar Kostadinov; Emily M Martersteck; Joshua R Sanes
Journal:  Neuron       Date:  2017-08-03       Impact factor: 17.173

Review 4.  SATB family chromatin organizers as master regulators of tumor progression.

Authors:  Rutika Naik; Sanjeev Galande
Journal:  Oncogene       Date:  2018-11-09       Impact factor: 9.867

5.  SATB2 and NGR1: potential upstream regulatory factors in uterine leiomyomas.

Authors:  Shun Sato; Ryo Maekawa; Isao Tamura; Yuichiro Shirafuta; Masahiro Shinagawa; Hiromi Asada; Toshiaki Taketani; Hiroshi Tamura; Norihiro Sugino
Journal:  J Assist Reprod Genet       Date:  2019-11-14       Impact factor: 3.412

6.  Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20.

Authors:  Ji Ae Lee; Mi-Kyoung Seo; Seung-Yeon Yoo; Nam-Yun Cho; Yoonjin Kwak; Kyoungbun Lee; Jung Ho Kim; Gyeong Hoon Kang
Journal:  Virchows Arch       Date:  2022-01-14       Impact factor: 4.064

Review 7.  microRNAs and Corresponding Targets Involved in Metastasis of Colorectal Cancer in Preclinical In Vivo Models.

Authors:  Ulrich H Weidle; Ulrich Brinkmann; Simon Auslaender
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

8.  Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.

Authors:  Arvydas Laurinavicius; Andrew R Green; Aida Laurinaviciene; Giedre Smailyte; Valerijus Ostapenko; Raimundas Meskauskas; Ian O Ellis
Journal:  Oncotarget       Date:  2015-12-01

9.  miR-449a inhibits colorectal cancer progression by targeting SATB2.

Authors:  Xiaohua Sun; Sanhong Liu; Pengfei Chen; Da Fu; Yingyong Hou; Jin Hu; Zhi Liu; Yuhang Jiang; Xinwei Cao; Chunyan Cheng; Xi Chen; Yu Tao; Cuifeng Li; Yiming Hu; Zhanjie Liu; Yu Zhan; Jie Mao; Qi Wang; Yushui Ma; Xianling Cong; Ran Sun; Yufang Shi; Mingliang Wang; Xiaoren Zhang
Journal:  Oncotarget       Date:  2016-07-28

10.  SATB1 and SATB2 play opposing roles in c-Myc expression and progression of colorectal cancer.

Authors:  Mohammed A Mansour; Toshinori Hyodo; Khondker Ayesha Akter; Toshio Kokuryo; Keisuke Uehara; Masato Nagino; Takeshi Senga
Journal:  Oncotarget       Date:  2016-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.